Table 5. Estimated effects of each other predictor when added singly to the primary model from Table 4.
Odds | 95% confidence interval | ||||
Predictor | Value | Ratio | Lower | Upper | P-value |
Sex | Male | 1.21 | 0.94 | 1.57 | 0.14 |
Race/ethnicitya | African American | 0.79 | 0.62 | 1.01 | 0.055 |
(vs Caucasian) | Hispanic | 1.26 | 0.91 | 1.75 | 0.17 |
Other | 1.23 | 0.85 | 1.79 | 0.27 | |
HIV-infectedb | Yes | 1.17 | 0.64 | 2.1 | 0.61 |
HIV-infected, by treatment erab | to 1995 | 0.68 | 0.17 | 2.7 | 0.58 |
(vs uninfected) | 1996 on | 2.1 | 0.97 | 4.4 | 0.059 |
HIV-infected, by treatment erab | to 1995 | 0.37 | 0.00 | 568 | 0.79 |
(vs uninfected) | 1996–1999 | 3.0 | 0.57 | 16.1 | 0.19 |
2000 on | 1.49 | 0.34 | 6.6 | 0.60 | |
Reported HCV risk factor | Transfusion | 0.99 | 0.72 | 1.37 | 0.96 |
(vs injection drug use) | Needlestick | 0.88 | 0.61 | 1.28 | 0.50 |
Other/None | 1.21 | 0.96 | 1.53 | 0.11 | |
Smoking | Yes | 1.07 | 0.83 | 1.40 | 0.59 |
Alcohol consumptionb,c | Moderate | 0.99 | 0.52 | 1.88 | 0.99 |
(vs none) | Heavy | 1.16 | 0.72 | 1.89 | 0.54 |
Injection drug useb | Yes | 0.92 | 0.69 | 1.23 | 0.58 |
Body Mass Index | per 5 Kg/m2 | 1.05 | 0.97 | 1.14 | 0.24 |
Body Mass Index | 25–30 | 1.09 | 0.88 | 1.36 | 0.42 |
(vs <25) | >30 | 1.19 | 0.95 | 1.50 | 0.14 |
This is an alternative finer breakdown instead of an addition to the primary model.
These are time-varying covariates, with potentially differing values at each time step.
This model was fitted on HALS participants only, because other studies lacked complete histories.
Abbreviations: HIV: human immunodeficiency virus; HCV: hepatitis C virus; HALS: Hepatitis C and Alcohol Study [16].